Resources from the same session
LBA4 - CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)
Presenter: Pilar Garrido Lopez
Session: Proffered Paper session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
LBA9 - Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)
Presenter: Ying Cheng
Session: Proffered Paper session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: Fiona Blackhall
Session: Proffered Paper session: Thoracic cancers
Resources:
Slides
Webcast
319O - ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC
Presenter: James Chih-Hsin Yang
Session: Proffered Paper session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
LBA6 - Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study
Presenter: Shun Lu
Session: Proffered Paper session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
LBA10 - A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)
Presenter: Wen Feng Fang
Session: Proffered Paper session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA6, LBA10 and 319O
Presenter: Ross Soo
Session: Proffered Paper session: Thoracic cancers
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Fiona Blackhall
Session: Proffered Paper session: Thoracic cancers
Resources:
Slides
Webcast